Johnson Financial Group LLC Cuts Position in Johnson & Johnson (JNJ)
Johnson Financial Group LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,276 shares of the company’s stock after selling 73 shares during the period. Johnson Financial Group LLC’s holdings in Johnson & Johnson were worth $301,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of the stock. Wallace Capital Management Inc. boosted its stake in Johnson & Johnson by 3.7% in the fourth quarter. Wallace Capital Management Inc. now owns 105,608 shares of the company’s stock valued at $12,168,000 after buying an additional 3,723 shares during the period. SRS Capital Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $752,000. Janus Capital Management LLC boosted its stake in Johnson & Johnson by 11.2% in the fourth quarter. Janus Capital Management LLC now owns 2,722,996 shares of the company’s stock valued at $313,717,000 after buying an additional 273,944 shares during the period. Cheviot Value Management LLC boosted its stake in Johnson & Johnson by 3.1% in the fourth quarter. Cheviot Value Management LLC now owns 107,813 shares of the company’s stock valued at $12,421,000 after buying an additional 3,245 shares during the period. Finally, Glassman Wealth Services boosted its stake in Johnson & Johnson by 29.9% in the fourth quarter. Glassman Wealth Services now owns 8,746 shares of the company’s stock valued at $1,008,000 after buying an additional 2,014 shares during the period. Institutional investors own 66.10% of the company’s stock.
Johnson & Johnson (JNJ) traded up 0.7047% during mid-day trading on Wednesday, reaching $134.3199. The company’s stock had a trading volume of 1,908,322 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company has a market capitalization of $360.51 billion, a PE ratio of 22.7276 and a beta of 0.78. The firm has a 50 day moving average price of $132.93 and a 200-day moving average price of $126.81.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the previous year, the business earned $1.74 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
TRADEMARK VIOLATION NOTICE: “Johnson Financial Group LLC Cuts Position in Johnson & Johnson (JNJ)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/johnson-financial-group-llc-cuts-position-in-johnson-johnson-jnj/1496078.html.
Several equities research analysts have recently commented on the company. UBS AG restated a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a research note on Monday, May 15th. J P Morgan Chase & Co upped their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday. Jefferies Group LLC set a $145.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday. Wells Fargo & Company restated a “market perform” rating and set a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target for the company. in a research note on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $134.12.
In other news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.